<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799160</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/052/16</org_study_id>
    <nct_id>NCT02799160</nct_id>
  </id_info>
  <brief_title>Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations</brief_title>
  <acronym>Paracentesis</acronym>
  <official_title>Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humboldt-Universität zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study evaluates the clinical, biochemical and haemodynamic effects of
      large-volume paracentesis (LVP) in 50 patients with and without signs of inflammation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ascites is one of the common complications in advanced liver cirrhosis. Large-volume
      paracentesis (LVP) is a widely used symptomatic intervention to remove large amounts of
      peritoneal fluid. Despite a low rate of interventional-associated complications like fistula
      or non life-threatening bleeding LVP induces an impairment of circulatory function. The
      hypothesis is that haemodynamic changes can be detected by non-invasive monitoring and that
      these haemodynamic changes could be associated to postinterventional organ dysfunction or
      complications. Additionally the investigators hypothesize that paracentesis-induced
      circulatory dysfunction could also be associated to present clinical and laboratory signs of
      inflammation or infection and could influenced by increased viable and non-viable bacterial
      translocation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change over time of stroke-volume (milliliter) before, under and after paracentesis</measure>
    <time_frame>10 minutes prior to start of paracentesis and 30 minutes, 60 minutes, 12 hours, 24 hours, and 48 hours after start of paracentesis</time_frame>
    <description>Baseline Monitoring 10 minutes before paracentesis, under paracentesis, 12 hours, 24 hours and 48 hours after paracentesis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change over time of arterial pressure (millimeter of mercury) before, under and after paracentesis</measure>
    <time_frame>10 minutes prior to start of paracentesis and 30 minutes, 60 minutes, 12 hours, 24 hours, and 48 hours after start of paracentesis</time_frame>
    <description>Baseline Monitoring 10 minutes before paracentesis, under paracentesis, 12 hours, 24 hours and 48 hours after paracentesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>Over the full time of paracentesis, 12 hours and 48 hours and up to 2 weeks after paracentesis</time_frame>
    <description>Clinical, laboratory and haemodynamic adverse effects of paracentesis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Paracentesis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Ascites fluid, serum and plasma probes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of the Medical Department, Division of Hepatology and Gastroenterology (including
        Metabolic Diseases)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male Patients between 18-70 years with liver cirrhosis and ascites

          -  Indication for paracentesis

        Exclusion Criteria:

          -  Infectious disease in the last 4 weeks

          -  Active alcohol-consumption or missing data of alcohol use

          -  Missing inform consent

          -  Missing speech comprehension

          -  Neurological or psychiatric disease that compromise consenting

          -  Hepatic encephalopathy stage III (West-Haven criteria)

          -  Heart failure NYHA IV

          -  Renal insufficiency or hepatorenal syndrome

          -  Atrial fibrillation

          -  Pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wiedenmann Betram, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Charite Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donata Grajecki, Dr. med.</last_name>
    <phone>+49 30 450 564 002</phone>
    <email>donata.grajecki@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aarne Feldheiser, PD Dr. med.</last_name>
    <phone>+49 30 450 651143</phone>
    <email>aarne.feldheiser@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donata Grajecki</last_name>
      <phone>+49 30 450 564 002</phone>
      <email>donata.grajecki@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Aarne Feldheiser</last_name>
      <phone>+49 30 450 651143</phone>
      <email>aarne.feldheiser@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997 Aug;113(2):579-86.</citation>
    <PMID>9247479</PMID>
  </results_reference>
  <results_reference>
    <citation>Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solà R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):347-53.</citation>
    <PMID>15195901</PMID>
  </results_reference>
  <results_reference>
    <citation>Pozzi M, Osculati G, Boari G, Serboli P, Colombo P, Lambrughi C, De Ceglia S, Roffi L, Piperno A, Cusa EN, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994 Mar;106(3):709-19.</citation>
    <PMID>8119542</PMID>
  </results_reference>
  <results_reference>
    <citation>Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003 Jan;37(1):208-17.</citation>
    <PMID>12500206</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Dr. med. Donata Grajecki</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

